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At the present time, anti-inﬂammatory, immunomodulatory, or immunosuppressive treatments of multiple sclerosis (MS) are
mainly eﬀective in the early phases of the disease but are of less advantage in progressive phases. Current therapeutic strategies
of both primary and secondary progressive MS are rare. One alternative may be intrathecal application of triamcinolone
acetonide (TCA). Number of papers deal with advantages and disadvantages of intrathecal administration in MS. Former trials
lacked detailed selection of MS patients, with small sample sizes, low steroid dosages, and only a small number of intrathecal
administration of short acting steroids. The present paper summarizes recent trials performed following a diﬀerent treatment
regime. They were conducted in patients with progressive MS suﬀering mainly from spinal symptoms and documented a
signiﬁcant improvement of EDSS and walking distance (WD). Intrathecal TCA administration is a proposal to take into account
as one therapy option in patients with a progressive clinical course and predominantly spinal symptoms.
1.Introduction
Multiple sclerosis (MS) as one of the most frequent diseases
of the central nervous system (CNS) in young adults often
entails persistent physical and mental disability. The preva-
lence is assumed to be 400,000 people in the United States
and approximately 2,1 million people worldwide [1]. MS is
an immune-mediated demyelinating inﬂammatory disease.
Its natural history in most patients is marked by a chronic
progressive decline [2]. Mostly, MS begins with a relapsing
course (relapse remitting MS, RRMS). After years, it leads to
a progressive course (secondary progressive MS, SPMS) [3,
4]. Another form of MS, progressive-relapsing MS (PRMS),
is deﬁned as a progressive disease from onset with acute
relapses and with periods of progression between relapses.
Nearly 10% of MS patients develop primary progressive MS
(PPMS), which is deﬁned as a progressive type from onset
with temporary impairment. Regarding to the pathogenesis
of MS, two diﬀerent approximations are common. MS
is mainly characterized by multitopic inﬂammation and
demyelination.Asthediseaseproceeds,theroleofaxonalloss
and gliosis increases [5].
Hence, MS pathophysiology is much more complex
than assumed up to now. Consequently, one therapy with
a single immune mechanism cannot ﬁt such a com-
plex pathogenic disease. At the present time, the anti-
inﬂammatory, immunomodulatory, or immunosuppressive
treatments are mainly eﬀective in the early phase of the
disease but are of less advantage in the progressive phase
[6]. Therefore, an axon-protective therapy will be essential
to reduce disease progression [7]. Current treating strategies
of progressive MS are rare. Mitoxantrone is an FDA-
approved therapy option for progressive phase in MS.
Meanwhile, the application of glucocorticosteroids in the
treatment of relapses has been accepted. There is general
agreement that intravenous methylprednisolone (IVMP)
administration (1000mg daily for 3–5 days) is ﬁrst-line
therapy in the recovery from relapses [8–10]. Treatment with2 Multiple Sclerosis International
IVMP minimizes tissue damage and assists lesion recovery
in patients with RRMS [11]. IVMP recovers the blood-
brain barrier (BBB) by downregulating adhesion molecule
expression. Furthermore, it induces diﬀerent immunological
changes as inhibition of proinﬂammatory cytokines, lym-
phocyte apoptosis, and remyelination [12]. So, as of a result,
their immunosuppressive and anti-inﬂammatory power glu-
cocorticoids are established in the standard treatment for
acute relapses. Although IVMP could reduce the duration
of a relapse, no eﬀect on the exacerbation rate or on the
development of long-term disability was determined [13].
The beneﬁt of corticosteroids in the treatment of acute
relapseshasbeenexaminedinclinicaltrials.Anotherdouble-
blind, placebo-controlled, randomized trial of high-dose
methylprednisolone (1g IV daily for 5 days) was arranged
in 35 patients with PPMS [14]. A statistically signiﬁcant
amelioration of the expanded disability status scale (EDSS)
score was observed. This improvement persisted for at least 3
months. One phase II randomized controlled trial (RCT) in
RRMS compared the beneﬁt of repeated pulsed IVMP with
IVMP at the same dosage but administered only for relapses.
It could be demonstrated that pulsed IVMP decreased the
development of T1 black holes, brain atrophy progression,
and associated development of permanent disability [10].
On the other hand, pulsed application of intravenous
corticosteroids is related to transient and dose-dependent
side eﬀects, such as temporary mood disorders, gastric ulcer,
headache, and myalgia [15]. Chronic administration may
even result in more serious side eﬀects, such as hypertension,
hyperglycemia, decline of cardiac conditions, osteoporosis
and an increased incidence of fractures, hepatic steato-
sis, infection, cataract, and transient memory impairment
[16]. Consequentially, one interesting alternative may be
the intrathecal administration of triamcinolone acetonide
(TCA), which has been adopted for the treatment of many
other diseases. This paper reviews data on the eﬃcacy of
intrathecal steroid application in the treatment of MS. Trials
were classiﬁed according to the system established by the
American Academy of Neurology (AAN) [17].
2. HistoricalExperienceswith Intrathecal
Steroids in Multiple Sclerosis
An u m b e ro fh i s t o r i c a lp a p e r sd e a lw i t ha d v a n t a g e sa n d
disadvantages of intrathecal administration in MS. Since
1953, several mainly uncontrolled trials have been pub-
lished. Diﬀerent dosages and diverse conventional steroid
compounds, that is, methylprednisolone acetate (MPA) or
TCA, are mentioned. Despite the controversial discussion
especially in progressive MS patients with predominantly
spinal symptomatology according to some trials, positive
eﬀects could be noticed [18–20]( Table 1).
In 1953, Kamen and Erdman [23] referred treating a
patient with RRMS with intrathecal hydrocortisone (HC)
and intramuscular adrenocorticotropic hormone (ACTH).
The patient recovered during a 6-week follow up. In a couple
of open-label, uncontrolled trials between 1961 and 1963,
Boines [24, 25] reported 75–80% recovery, particularly of
spasticity with intrathecal MPA in 42 patients during a
follow up of 12–52 weeks. Goldstein et al. [30]r e p o r t e d
that intrathecal MPA decreased CSF γ-globulin in MS
but without correlation to improvement of spasticity. In
1964, Van Buskirk et al. [26] performed an open-label,
uncontrolled prospective study of intrathecal MPA in 20
patients. The treatment appears to decrease spasticity in
14 patients and consequently results in improved walking
distance and bladder function. In 1970, again Goldstein et
al. [27] referred in an open-label, uncontrolled trial to 38
patients treated with 4 to 8 intrathecal MPA infusions and
followed up for 2 to 8 years. Neurological examinations
revealed an initial improvement in 30 patients that remained
stable in only 6 patients. In 1973, again Nelson et al. [28]
reported in an open-label, uncontrolled prospective study
on 23 patients with MS. They received intrathecal MPA
infusions for acute exacerbations. A mild amelioration of
EDSS was detected in 4 patients (17%). All the above-
mentioned studies have to be rated as class IV evidence, only.
For the ﬁrst time, Rohrbach et al. [29]p e r f o r m e da
double-blind, randomized, controlled trial (short report).
42 distinctly chronic progressive MS patients with predom-
inantly spinal symptoms were enrolled. One cohort was
treatedeitherwith3or4intrathecalTCAinjectionsof80mg.
The other cohort received oral triamcinolone starting with
48mg/d in descending dosage. In the intrathecal cohort,
a better and consistent improvement in the spinal score
could be observed than the other treatment arm. This study
corresponds to class II evidence.
In 1992, Heun et al. [18] conducted an open-label,
randomized, prospective, unblinded study on 50MS patients
with diﬀerent MS forms (RRMS, PPMS, and SPMS). One
group received 3 intrathecal TCA injections of 40mg on days
1, 8, and 15; the other cohort was treated with methylpred-
nisolone 100mg i.v. from day 1 to 5, then in descending
dose. A slender but signiﬁcant improvement in disability was
noticeable in both cohorts. No signiﬁcant diﬀerence in the
examined frequency of improved neurological symptoms or
in EDSS between the two cohorts was found. The study has
to be classiﬁed as class III evidence.
In conclusion, the majority of the mentioned historical
trials of intrathecal steroid for MS performed in the past
were uncontrolled and have to be rated as class IV evidence.
Despite their lacks, the trials of Rohrbach et al. [29]
a n dH e u ne ta l .[ 18] are notable (class II/III evidence).
Especially trials that conform to generally deﬁned criteria of
evidence-based medicine are missing. According to intrathe-
cal TCA applications, there is a controversial discussion
[19, 31]. Repeated lumbar punctures under double-blind
design including the agreement of patients and the ethical
committee are nowadays not feasible.
2.1. Risks. Intrathecal MPA therapy for MS caused transient
urinary incontinence in two of 20 patients [26]. In two
other reports on 61 patients, constrictive arachnoiditis in
thoracic or lumbar area, aseptic meningitis, subarachnoid
haemorrhage, and neurogenic bladder were described [27,
28]. Other mentioned complications were brain damage,Multiple Sclerosis International 3
Table 1: Representative intrathecal steroid trials 1953–1992 [21, 22].
Design
Patients
included,
MS type
Dosage and duration Primary outcome Results Evidence
Kamen and
Erdman, 1953
[23]
Case report 1; RR
Intrathecal HC and
intramuscular ACTH;
no speciﬁc data available
Recovery Patient recovered IV
Boines, 1961
and 1963
[24, 25]
Open-label, uncontrolled,
retrospective, unblinded
follow up of 12–52 weeks
42; no
speciﬁc data
available
40–100mg intrathecal
MPA every 2-3 weeks for
a total of 6 injections,
then “follow-up booster
injections”
“recovery,
particular of
spasticity”; no
speciﬁc outcome
data available
“80% of patients
improved/showed
excellent or good
results”
IV
Van Buskirk
et al.,
1964 [26]
Open-label, uncontrolled,
prospective, unblinded
20; no
speciﬁc data
available
Weekly increasing doses
intrathecal MPA
(20–80mg), then
booster injection
monthly (80–100mg
MPA); follow up 1
week-16–months
“clinical
improvement”
“no eﬀect on
frequency of
exacerbations, but
improvement in
spasticity in 14
patients”
IV
Goldstein
et al.,
1970 [27]
Open-label, uncontrolled,
retrospective, unblinded
38; no
speciﬁc data
available
40–80mg intrathecal
MPA/4–8 times within
1-2 weeks; follow up 2–8
years
“improvement” “79%
improvement” IV
Nelson et al.,
1973 [28]
Open-label, uncontrolled,
prospective, unblinded 23; RR, SP
40–120mg intrathecal
MPA/1–23 times within
2m o n t h s ;f o l l o wu p
1–84 months
EDSS CSF
changes
EDSS: 4 patients
(17%) improved;
signiﬁcant increase
of CSF protein
IV
Rohrbach
et al.,
1988 [29]
double-blind,
randomized, prospective
42, “mainly
chronic
progressive”
Intrathecal TCA:
80mg/3-4 times within
14 days
Oral TCA: 48mg/d,
tapering oﬀ
“spinal score”
Intrathecal TCA:
“better
improvement in
the spinal score”
II
Heun et al.,
1992 [18]
open-label, prospective,
randomized, unblinded,
follow up of 21 days
Intrathecal
TCA: 25
Systemic
MPA: 25
TCA: 40mg on days 1, 8,
and 15
MPA: 100mg for 5 days,
tapering oﬀ
EDSS AI SSEP
EDSS improved in
both groups
(P<. 01);
EDSS changes
between both
groups n.s.; AI n.s.
III
TCA: triamcinolone-acetonide acid; HC: hydrocortisone; ACTH: adrenocorticotropic hormone; MPA: methylprednisolone acetate; RR: relapsing-remitting
MS; PP: primary chronic progressive MS; SP: secondary chronic progressive MS; MIX: mitoxantrone, EDSS: expanded disability status scale; WD: maximum
walking distance; WT: maximum walking time; SSEP: somatosensory evoked potentials; AI: ambulation index; CSF: cerebrospinal ﬂuid; n.s: non signiﬁcant.
spinal cord lesions, and dense widespread pachymeningitis
[32–34]. In spite of these reports, intrathecal steroid therapy
is still advised [21, 35].
3.Recent TrialswithIntrathecal
TCA AdministrationinProgressive
Multiple Sclerosis
The revival of intrathecal steroid treatment started with
the positive results of a trial on intractable postherpetic
neuralgia, in which 89 subjects received up to 4 intrathecal
methylprednisolone administrations within 4 weeks without
any serious side eﬀects [36]. In a rapid succession, a
few further open-label uncontrolled trials were performed
following a diﬀerent treatment regime [37–39]( Table 2).
Hoﬀmann et al. [37] performed an open-label, uncon-
trolled, prospective trial on the short-term and long-term
eﬃcacy and tolerability of repeated intrathecal TCA appli-
cation. 36 patients with progressive MS (22 SPSS, 14 PPMS,
EDSS < 7.5) were included. Patients did not receive steroids
and were on a stable immunomodulatory drug treatment for
atleast4weeksbeforethestartofthestudy.Theyhadtoshow
symptomprogressionofatleastonepointontheEDSSscale,
in the last 2 years before study entry, but had to be stable for
at least 4 weeks before inclusion. An atraumatic (Sprotte)
needle was used in order to minimize the risk of postlumbar
puncture syndrome [41]. 6 injections with 40mg TCA
were administered within 3 weeks. EDSS scores signiﬁcantly
decreased (P = .00065), and the walking distance (WD)
signiﬁcantly increased (P = .003). None of the measured
parameters deteriorated in any patient. Patients with an
improvement in their EDSS or WD were provided to receive
further treatment with one TCA application at an individual
rate every 6 to 12 weeks. The follow-up treatment period
amounted to 13.1 ± 6.22, 3–23 (mean ± S.D., range) months4 Multiple Sclerosis International
Table 2: Representative intrathecal steroid investigations in multiple sclerosis (since 2003).
Design
Patients
included,
MS type
Dosage and duration
Primary and
secondary
outcomes
Results Evidence
Hoﬀmann
et al.,
2003 [37]
Open-label, prospective,
uncontrolled,
unblinded,
short follow up
36 (SP, PP)
TCA 40mg/6 times
within 3 weeks; follow
up with 40mg every
6–12 weeks; 13.1 ± 6.22,
3–23 (mean ± SD.,
range) months
EDSS WD
initial phase:
EDSS (initial 5.6 ± 0.93
(mean ± S.D.); end: 4.9
± 1.0; P<. 001).
WD: (initial: 294 ±
314m; end: 604 ±
540m; P<. 001) follow
up: EDSS and WD
remained stable
IV
Hellwig et al.,
2004 [38]
Open-label, prospective,
uncontrolled,
unblinded,
short follow up
161 (RR, SP,
PP)
TCA 40mg/6 times
within 3 weeks EDSS WD SSEP
EDSS: (initial: 6.44 ±
1.06; end: 5.47 ± 1.24):
WD: (initial 158.03 ±
501.20, end: 439.38 ±
895.24).
SSEP latencies: reduced
for all variables
(P<. 0001)
IV
Hoﬀmann
et al.,
2006 [39]
Open-label, prospective,
uncontrolled,
unblinded, short follow
up
27 (SP, PP) TCA 40mg/6 times
within 3 weeks
EDSS WD WT
25-f-test CSF
changes
EDSS: (initial: 5.4 ±
1.3; end: 4.9 ± 1.1;
P<. 001).
WD and WT increased:
P<. 001, 25 f-test
increased: P<. 01 CSF
changes n.s.
IV
Hellwig et al.,
2006 [40]
open-label over a
52-week long interval,
prospective,
randomized, unblinded
TCA: 34
(SP, PP)
MIX: 30
(SP, PP)
TCA: 40mg every 6–12
weeks, 52 weeks
MIX: initial dose:
12mg/m2 2nd dose:
8–10mg/m2 6w e e k s
later/then quarterly: 52
weeks
EDSS WD
TCA: EDSS decreased
(P<. 001)
WD: increased
(P<. 001)
MIX: EDSS, WD n.s.
III
TCA: triamcinolone-acetonide acid; RR: relapsing-remitting MS; PP: primary chronic progressive MS; SP: secondarychronic progressive MS; MIX:
mitoxantrone;EDSS:expandeddisabilitystatusscale;WD:maximumwalkingdistance;WT:maximumwalkingtime;SSEP:somatosensoryevokedpotentials;
CSF: cerebrospinal ﬂuid; n.s: non signiﬁcant.
with 6.35 ± 3.91, 2–15 TCA administrations. The post hoc
analysis demonstrated that a signiﬁcant decline of EDSS
and the improvement of WD occurred after ﬁrst initial
6 TCA applications and then remained stable. Neither a
signiﬁcant impact of covariates in statistical analysis nor
relevant side eﬀects were found. This study accomplished
a total of 340 lumbar punctures. A temporary increase
of CSF protein above 500mg/L and transitory increase of
CSF cells (maximum cell count was 38/μL) was noticed.
Nevertheless, no new clinical symptoms were caused in
any subject. 5 patients developed a slight post-lumbar
puncture syndrome, but they did not abandon further TCA
applications. This study illustrated eﬃcacy and safety of
repeated intrathecal TCA administration in progressive MS
patients with spinal symptoms. The application frequency
(6 TCA injections within 3 weeks and follow-up injection
every6to12weeks)wasmarkedlyhigherincontrasttoother
previous trials. This analysis demonstrated that particularly
PPMS and SPMS patients beneﬁt from described therapy
design. Although long-term data did not prove any further
improvement of neurological symptoms, the amelioration
reachedremainedrobustoverthefollowingtreatmentperiod
with one TCA application every 6 to 12 weeks. Nevertheless,
this uncontrolled study has to be graduated as class IV
evidence.
Hellwigetal.[38]performedanotheropen-label,uncon-
trolled, prospective study on 161 MS patients (35 PPMS,
122 SPMS, 4 RRMS) with pronounced spinal symptoms on
the impact of the administration of 40mg of the sustained
released steroid TCA. Subjects did not suﬀer from an acute
onset of exacerbation or recent pronounced increased pro-
gression of MS symptoms. An established immune system
modulating therapy was not altered. EDSS, Barthel index,
WD, and somatosensory evoked potentials (SSEPs) were
analysed before start and at the end of the TCA treatment
[42]. The patients achieved a supplemental standardized
rehabilitation therapy. Atraumatic Sprotte needles were
usedtoavoidpost-lumbarpuncturesyndrome[41,43].Each
patient received 6 applications of 40mg TCA within 3 weeks.
EDSS and Barthel indices were enhanced, WD increased,Multiple Sclerosis International 5
and latencies of SSEP of the median and tibial nerves were
reduced in all patients at serial evaluation (P<. 0001 for
all variables). Neither slight nor severe side eﬀects were
registered. 5 patients abandoned the study due to lumbar
puncture headache.
In this uncontrolled trial, an improvement of spinal
symptoms, WD, and SSEP latencies in progressive MS
patients were documented, and the results from a previous
t r i a lw e r ec o n ﬁ r m e d[ 37]. The electrophysiological results
may mirror a certain potential of intrathecal TCA admin-
istration for demyelinating actions. Again this uncontrolled
study has to be rated as class IV evidence.
3.1. Absent Hints as to Cell Injury by Repeated TCA Appli-
cations. Steroids were suspected to induce a neuronal cell
injury due to brain atrophy [10, 22, 44]. Another open-
label, uncontrolled, prospectice trial on short-term eﬃcacy
of repeated intrathecal TCA applications in progressive MS
dealt with this aspect [39]. 27 subjects with progressive MS
were included. They received similar therapy as described
in previous trials [37, 38]. In addition to the mentioned
clinical parameters, CSF was examined for the unspeciﬁc
markers of cell injury neuron-speciﬁc enolase (NSE), Tau-
protein, S 100B, and β-amyloid [45–49]. 6 TCA injections,
performed every third day, reduced EDSS (initial: 5.4 ± 1.3,
3–7.5 (mean ± SD, range); end: 4.9 ± 1.1; 2.5–6.5; P<. 001)
and signiﬁcantly increased WD primarily after the fourth
TCA injection. These results indicated that the role of TCA
administrations is undercharged in those trials without any
persuasive clinical output [18, 20]. The assessed CSF marker
did not signiﬁcantly change within the interval of TCA
treatment. This supported the statement that the sustained
released steroid TCA is not toxic and causes no relevant cell
injury or deterioration of neuronal cells [10, 20, 44, 50–53].
Furthermore, no serious clinical side eﬀects appeared. This
uncontrolled study has to be classiﬁed as class IV evidence.
3.1.1. Comparison of Repeated Intrathecal TCA Administra-
tion with Mitoxantrone Therapy in Patients with Progres-
sive MS. Previous studies showed that repeated intrathecal
TCA administrations generated a clear prolonged beneﬁt
in patients with progressive MS suﬀering from mainly
spinal symptoms [37]. Mitoxantrone (MIX) application
is performed similarly in progressive MS patients with a
continuous, rapid worsening of symptoms [54]. In contrast
to TCA administration, MIX application is a worldwide
accredited therapy to diminish or abandon progression.
There exists important restriction due to its cardiac toxicity.
Hence, a cumulative maximal life-time dose should be
respected [54–56].
Based on this consideration, Hellwig et al. [40]p e r -
formedanopen-labelstudyovera52-week-longintervaland
compared TCA and MIX therapy in two matched cohorts of
subjects with progressive MS. Only patients with progressive
MS with an EDSS ≤ 7.5 were recruited. In the MIX arm,
30 patients were included and observed over 1 year. The
initial MIX dose was 12mg/m2. The second infusion was
followed 6 weeks later and then quarterly. The MIX dose was
minimizedto10mg/m2 and8mg/m2 dependentonpatients’
stable condition. 34 patients were recruited in the TCA arm
and treated as previously described [37]. EDSS signiﬁcantly
decreasedandWDsigniﬁcantlyincreased(P<. 001)afterthe
initial 6 TCA administrations and then remained relatively
constant. Neither EDSS nor WD deteriorated in any of the
TCA patients. On the other hand, MIX therapy did not
signiﬁcantly inﬂuence EDSS (P = .056) or WD (P =
.12), even though no additional decline of EDDS or WD
was measured. Two patients in the MIX arm suﬀered from
moderate nausea. An isolated and temporary increase in
CSF protein (>5 0 0 m g / L )a n dat e m p o r a r yr i s eo fC S F
cells without development of neurological symptoms in all
subject was observed. 8 patients in the TCA arm suﬀered
from post-lumbar puncture syndrome without termination
of further TCA treatment. Again, the eﬃcacy and safety of
repeated intrathecal TCA administrations in progressive MS
patients with predominantly spinal symptoms was approved
[37, 38]. It has to be pointed out that a rate with 6 TCA
applicationswithin3weekswasdeﬁnitivelyhighercompared
to previous trials [18]. Following this concept, especially
PPMS and SPMS patients appear to improve initially and
then remain stable during TCA treatment at least over one
year. In contrast in this trial, MIX therapy did not improve
EDSS or WD, but no signiﬁcant impairment was recognized.
O t h e rt r i a l sa p p r o v e dap o s i t i v ei m p a c to fM I Xo nM S
symptoms especially in patients with progressive MS and
superposed relapses [54, 57, 58]. The number of relapses in
the year before MIX treatment started is regarded to be a
predictive parameter in MIX eﬃcacy in MS patients [59].
In this trial, mainly patients without superimposed relapses
were included. Therefore, the lack of EDSS improvement
could be attributed to this. In conclusion, TCA and MIX
proved their eﬃcacy in diﬀerent ways. Maybe a combination
of both should be investigated in progressive MS patients as
it has been performed with IVMP and MIX [60]. Despite the
mentioned limitations, this study has to be rated as class III
evidence.
4. Conclusion
Up to now, clinical trials on patients with progressive MS
demonstrated no distinct proof of a potent symptomatic
treatment intended to improve or at least stabilize dis-
ability, as soon as the progressive phase of the disease
stage appears. Immunomodulatory treatment minimizes
the rate of MS relapses noticeably but shows no evident
positive eﬀects in patients with progressive MS [17]. So
the immunomodulatory treatment is a rather preventive
one. Numerous papers dealt with the eﬃcacy of intrathecal
application of diﬀerent dosages of various released steroid
compounds, above all methylprednisolone acetate was used.
This formerly used steroids were mainly short acting cor-
tisone derivates. Further, these steroids were administrated
intrathecally less frequently. So, these trials lacked of detailed
selection and clinical characterization of MS patients, with
small sample sizes, low steroid dosages, and only a few
intrathecal administration of mostly short-acting cortisone
derivates [19, 20, 36]. Beneﬁcial but controversialy discussed6 Multiple Sclerosis International
eﬀects were mentioned in progressive MS patients with
predominantly spinal symptoms according to case reports,
open-label trials, and one double-blind, controlled study
(class of evidence II) with the sustained released steroid TCA
[18–20]. As is known, the anti-inﬂammatory impact of a
steroid application depends not only on the dosage but also
on the duration of exposure [9, 10, 61]. Hence, the frequency
ofapplicationandtheutilizationofadelayedreleasedsteroid
derivative as TCA are recommendable.
In a rapid succession, a few further open-label uncon-
t r o l l e dt r i a l sw e r ep e r f o r m e df o l l o w i n gad i ﬀerent treatment
regime [37–39]. 6 injections of 40mg of the sustained
released steroid derivate TCA were administered within 3
weeks. Patients with an improvement of EDSS or WD
were provided to receive further treatment with one TCA
application in an individual rate every 6 to 12 weeks. All
forecited more recent open label trials were performed in
patients with progressive MS with mainly spinal symptoms.
They documented a signiﬁcant improvement of EDSS and
WD, respectively. With additional administrations, a stable
eﬀect was achieved. However, the mechanism which these
improvements are based on is unacquainted. One item
debated was the decrease of spasticity by the long-acting
steroid. But a signiﬁcant decrease of antispastic scores was
not essential to achieve the mentioned results in recent
trials. Another point of discussion could be that intrathecal
administration of a sustained released steroid circumvents
the BBB and has a positive impact on the still continuing
chronic inﬂammation process. The one thing common to
all the recent examples we gave was that they had all been
focused on progressive MS patients without signs of an acute
exacerbation.
T h eb e f o r e - d e s c ri b e dgr e a tn u m b e ro fs e ri o u ss i d ee ﬀects
could not be reproduced in the recent trials. There were
some raised concerns about a possible neuronal cell injury
promoting eﬀect induced by the administered steroid, with
inducing brain atrophy [10, 22, 44]. The additional serial
assessmentof potential unspeciﬁccellinjury markers,thatis,
NSE or S-100, in CSF of progressive MS patients treated with
repeated intrathecal TCA did not provide evidence of such a
steroid associated risk [39]. Particularly, the long half-life of
the applied sustained released steroids appears to be the key
of the missing proof of a toxic eﬀect. Further detailed trials
with examination of selected CSF biomarkers in MS patients
treated with intrathecal steroids are necessary to illuminate
these interesting aspects.
In general, further trials are needed to gain more results
about the utility of this therapy. All of the mentioned
historical and recent studies have to be classiﬁed just as
class II–IV evidence. The ideal trial design would be a
randomized, placebo-controlled, double-blind one. In this
case, repeated performance of intrathecal placebo applica-
tion under double-blind conditions with the consent of
patients and the ethical committee seems not to be realistic.
Furthermore, such a design including withholding treatment
causes maybe ethical qualms [62]. Contrariwise, one could
claim that due to the limited evidence for eﬃcacy of
intrathecal TCA treatment, the only existing open-label, not
placebo-controlled study with repeated lumbar punctures is
unethical without level A evidence.
From this point of view, further trials on the potency
and safety of intrathecal TCA applications are needed. A
multicenter clinical study has to be established to evalu-
ate these items and to compare systemic and intrathecal
steroid treatment, initially in progressive MS patients with
predominantly spinal symptoms and afterwards in patients
with an acute relapse. In addition to the investigation of
the long- and short-term beneﬁts, potential risks related to
the intrathecal application have to be examined in a blinded
analysis. Furthermore, the potential eﬃcacy of intrathecal
TCA treatment combined with MIX in progressive MS has
to be explored [60].
Anyhow, the intrathecal TCA administration has to be
taken into account as one therapy option in handpicked
MS patients with a slow progressive clinical course with
predominantly spinal symptom features. The intrathecal
TCA application should be oﬀered by neurologists with a
comprehensive experience in this special treatment. In fact,
an individual risk-beneﬁt analysis and the patient’s approval
are required.
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